Fig. 1

Flowchart for the antiviral selection in patients with mild to moderate COVID-19. COVID-19, the coronavirus disease 2019; DDIs, drug-drug interactions; eGFR, estimated glomerular filtration rate; MOV, molnupiravir; NMV-r, nirmatrelvir/ritonavir